HC Wainwright Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM) had its target price raised by equities researchers at HC Wainwright from $230.00 to $245.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 64.13% from the company’s previous close.

Several other research analysts have also issued reports on INSM. Guggenheim decreased their price target on shares of Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Wolfe Research set a $167.00 price objective on Insmed and gave the stock an “outperform” rating in a research note on Thursday, December 18th. Mizuho lifted their target price on Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a report on Wednesday. Wells Fargo & Company cut their target price on Insmed from $208.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, UBS Group reduced their target price on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a report on Tuesday, January 6th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Insmed presently has an average rating of “Buy” and an average target price of $210.19.

Insmed Price Performance

Shares of NASDAQ:INSM traded up $0.97 during trading hours on Thursday, hitting $149.28. 530,975 shares of the company’s stock traded hands, compared to its average volume of 2,450,212. Insmed has a 52 week low of $60.40 and a 52 week high of $212.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The company’s fifty day simple moving average is $150.68 and its two-hundred day simple moving average is $166.11. The company has a market cap of $32.18 billion, a price-to-earnings ratio of -23.30 and a beta of 1.13.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. The firm’s revenue for the quarter was up 152.6% compared to the same quarter last year. As a group, equities analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In other Insmed news, COO Roger Adsett sold 791 shares of Insmed stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total transaction of $123,530.47. Following the completion of the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at $16,680,517.70. This trade represents a 0.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 748 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total value of $116,942.32. Following the completion of the transaction, the chief financial officer owned 79,758 shares in the company, valued at $12,469,365.72. This trade represents a 0.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 189,651 shares of company stock valued at $31,533,654 over the last ninety days. 3.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insmed

Institutional investors have recently made changes to their positions in the company. CoreCap Advisors LLC bought a new stake in shares of Insmed in the 4th quarter valued at approximately $27,000. Reflection Asset Management bought a new position in Insmed during the fourth quarter valued at approximately $30,000. GraniteShares Advisors LLC bought a new position in Insmed during the fourth quarter valued at approximately $30,000. CIBC Private Wealth Group LLC lifted its stake in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the last quarter. Finally, Raiffeisen Bank International AG acquired a new stake in Insmed in the fourth quarter valued at approximately $32,000.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Positive Phase 3b ENCORE topline results for ARIKAYCE in MAC lung disease — supports possible label expansion to 1st‑line patients, which would materially enlarge the addressable market and boost revenue visibility. Insmed reports positive topline results from phase 3b ENCORE study of Arikayce
• Positive Sentiment: Multiple analyst upgrades/target raises following the trial news — Stifel raised its price target to $208 and Mizuho bumped its target to $206; Bank of America and Leerink Partners also published bullish notes saying the stock should rise. These upgrades increase upside expectations and support buy-side momentum. Leerink Partners Analyst Says Stock Expected to Rise Bank of America Analyst Says Stock Expected to Rise Stifel Boosts Price Target to $208 Mizuho Raises Target to $206
• Positive Sentiment: Bullish equity commentary highlights commercial momentum and pipeline optionality — Seeking Alpha and other analysts argue ARIKAYCE label expansion plus BRINSUPRI sales underpin strong upside and multi‑product revenue growth. Seeking Alpha: Possible Label Expansion Bodes Well
• Positive Sentiment: Management disclosure that Japan’s MAC patient population exceeds the U.S. — suggests a larger international addressable market for ARIKAYCE and potential upside from Japanese label/regulatory plans. Insmed CEO: Japan Patient Population Exceeds US Market
• Neutral Sentiment: Valuation and analyst discussion pieces are digesting the new data — several outlets review updated valuation assumptions and potential upside if label expansion and converted approvals materialize. These help set expectations but are not new catalysts by themselves. Yahoo Finance Valuation After Positive Data
• Neutral Sentiment: Reported short‑interest increases appear in data feeds but the published figures are inconsistent/erroneous (zeros/NaN) — monitor for credible updates; a genuine short squeeze or cover could amplify moves, but current reports are unreliable.
• Negative Sentiment: Wells Fargo trimmed its price target to $175 — a more conservative view that tempers some upside and gives investors an alternative, lower valuation anchor. Wells Fargo Lowers Price Target to $175

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.